Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited       IL0006290147

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

SummaryChartsNewsRatingsCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Teva Pharmaceutical Industries Limited : Teva Calls 5.550% Senior Notes Due 2016 for Redemption

share with twitter share with LinkedIn share with facebook
share via e-mail
03/01/2013 | 09:20am EDT

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that its finance subsidiary Teva Pharmaceutical Finance Company, LLC has called for redemption its approximately $500 million outstanding principal amount of 5.550% Senior Notes due 2016 (CUSIP No. 88163V AC3). The redemption is being funded with cash on hand.

The redemption date will be March 22, 2013, and the redemption price will equal the principal amount of the notes plus a make whole premium calculated in accordance with the terms of the applicable indenture. On the redemption date, the redemption price, together with accrued and unpaid interest from February 1, 2013, to, but excluding, the redemption date, will become due and payable on the notes.

Details concerning the redemption price and the other terms and conditions of the redemption will be more fully described in a Notice of Redemption being provided to registered holders of the notes by The Bank of New York Mellon, as trustee. Holders of notes who have questions should contact Joellen McNamara of The Bank of New York Mellon at 1-212-815-5587 or via email at joellen.mcnamara@bnymellon.com, or Teva's investor relations department at (215) 591-8912 or (011) 972-3-926-7656.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
Kristen Frank, 215-591-8908
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Hadar Vismunski-Weinberg, 972 (3) 926-7687
or
United States
Denise Bradley, 215-591-8974


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on TEVA PHARMACEUTICAL INDUST
2019TEVA PHARMACEUTICAL INDUSTRIES : FTC Reach Tentative Settlement in Low-Cost Gene..
DJ
2019TEVA PHARMACEUTICAL INDUSTRIES : U.S. settles with Teva over keeping generic dru..
RE
2019TEVA PHARMACEUTICAL INDUSTRIES : FTC Reach Tentative Settlement in Low-Cost Gene..
DJ
2019TEVA PHARMACEUTICAL INDUSTRIES : Finalizes Settlement with Federal Trade Commiss..
BU
2019TEVA PHARMACEUTICAL INDUSTRIES : FDA Approves Teva's Generic Version of Epilepsy..
DJ
2019Drug companies greet 2019 with U.S. price hikes
RE
2018TEVA PHARMACEUTICAL INDUSTRIES : to Report Second Quarter 2018 Financial Results..
BU
2018Trump slams Pfizer after July 1 drug price hikes
RE
2018TEVA PHARMACEUTICAL INDUSTRIES : Announces Launch of a Generic Version of Uceris..
BU
2018ADRs End Higher
DJ
More news
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Eric Drapé Executive Vice President-Global Operations
Eli Kalif Chief Financial Officer & Executive Vice President
Amir Elstein Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED0.39%8 281
JOHNSON & JOHNSON-15.57%324 693
ROCHE HOLDING AG-5.53%264 026
MERCK & CO., INC-15.39%181 927
NOVARTIS-17.30%180 007
PFIZER, INC.-16.62%171 422